|
|
|||||||||||||||
|
|
Biomyx is devoted to bring the latest technology
and tools to biomedical researchers. Technology development at Biomyx focuses
mainly in the general areas of functional genomics and proteomics. We are
exploring applications for our proprietary ProLinkTM and
Direkt-siRNATM technologies in areas including high
throughput functional genomics, drug discovery, and protein therapeutics. We
welcome collaborations, co-development or co-commercialization of these
technologies. |
||||||||||||||
|
Direkt-siRNATM Enabling technology for systematic knock-down of
gene expression and for automated, high throughput gene function analysis in
mammalian cells To overcome the limitations of using chemically
synthesized double strand siRNAs, Biomyx developed a series of proprietary
DNA oligo-based means of silencing gene expressions in mammalian cells.
pH1-siRNA and pU6-siRNA (siRNA
Vectors) are mammalian expression vectors developed at Biomyx. A chosen
sequence (from the targeted mRNA) cloned easily into the vectors as a
inverted repeat under the promoter will be expressed in mammalian cells as a
hairpin structure and processed in vivo to produce siRNA, which
initiate the RNA interference effects. They offer researchers the choice of
either one of the two most widely used promoters for expressing siRNA: the
human H1 RNA promoter or the mouse U6 snRNA promoter. They are small in size
and user-friendly. Both vectors have a G418 resistant gene expression
cassette enabling the selection of stable cell lines expressing the desired
siRNA. As compared with the use of synthetic or in vitro transcribed siRNAs,
these DNA -based approaches are cost efficient, more consistent and can be
integrated into the genome to study long-term effects of siRNAs. The making of these vectors, however, is time
consuming and hence limiting our ability in exploring the full power of RNAi.
It is generally believed that only one out of 5 siRNA sequences will be very
effective in knocking down. To find an effective siRNA sequence for a given gene,
many expression vectors need to be constructed, not mentioning the systematic
knock-down of many genes simultaneusly. To meet the need of high throughput,
systematic gene function studies, Biomyx developed the proprietary Direkt
siRNA technology that allows fast generation, delivery and expression of
many siRNAs at minimal cost. The technology will enable researchers to scan
mRNA or untranslated sequences for effective siRNA sequences, or to study the
effects of siRNAs for many genes in a matter of days, which is impractical
with synthetic dsRNA or expression vector based methods. ProLinkTM: Novel technology for
studying protein function directly and for improving proteins of diagnostic
and therapeutic values Biomyx is devoloping a novel protein ligation
system that’s able to enzymatically join any recombinant proteins efficiently
with a short consensus sequence to another protein or short peptide. The
system enables site-specific labeling, modification or immobilization of
protein molecules and will find applications in many fields using protein as
the tool or the subject, including protein engineering, protein-protein
interactions, proteomics, and protein delivery. The system will have great
impact on diagnostics and therapeutic as well. With this system, the potency,
target selectivity or in vivo stability of many recombinant diagnostic
and therapeutic proteins (e.g. recombinant antibodies or growth factors) can
be dramatically improved while their biological activities of diagnostic and
therapeutic value are fully retained. For these proteins, it’s extremely
important to reserve their biological activities as it takes a lot of time,
effort and money for a drug to be approved and marketed. |
|||||||||||||||
|
ã 2005 Biomyx Technology ·
10054 Mesa Ridge Court Ste. 112 · |